News & Events
Topline Results from Paltusotine Phase 3 PATHFNDR-2 Study
Event Date: March 19, 2024
READ MORECrinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
Crinetics Pharmaceuticals reports positive topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety...
READ MORECrinetics Presents Data from Phase 2 Study of Paltusotine in Carcinoid Syndrome
Event Date: March 12, 2024
READ MORECrinetics Announces Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Crinetics announces positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational...
READ MORECrinetics Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new...
READ MORECrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals today reported financial results for the fourth quarter and full year ended December 31, 2023.
READ MORECrinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
Crinetics announces that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per...
READ MORECrinetics Pharmaceuticals To Report Fourth Quarter And Full Year 2023 Financial Results On February 28, 2024
Event Date: Crinetics will host a conference call and webcast on February 28th at 4:30 p.m. ET to discuss fourth quarter and full year 2023 financial results and provide a business update.
READ MORECrinetics Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 73,000 shares of its common stock to nine new...
READ MORECrinetics Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 112,500 shares of its common stock to eight new...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
